MDL 62211 is the amide derivative of the teicoplanin complex and MDL 62873 is a more focused amide derivative of the teicoplanin A2-2 peak. Each investigational compound had nearly identical activity and was 2-to 16-fold more active than teicoplanin or vancomycin. The MDL 62873 MICs for 90% of the strains tested were as follows: Staphylococcus aureus, oxacillin susceptible, 0.12 ,ug/ml; S. aureus, oxacillin resistant, 0.25 ,ug/ml; coagulase-negative staphylococci (CNS), oxacillin susceptible, 0.25 ,ug/ml; and CNS, oxacillin resistant, 2 ,ug/ml. CNS isolates from France were generally more susceptible than those tested in the United States. Teicoplanin-resistant U.S. isolates were usually Staphylococcus haemolyticus (1.8% of all tested strains), for which MICs ranged from 32 to >128 ,ug/ml. MDL 62873 was not active against the Bacteroides fragilis group but was generally effective against gram-positive anaerobic strains.
The glycopeptide vancomycin has emerged in the 1980s as a reliable therapeutic agent for the therapy of serious infections caused by oxacillin-resistant staphylococcal strains or as an alternative drug for patients with penicillin allergy or macrolide intolerance. Recently, some reports of glycopeptide-resistant coagulase-negative Staphylococcus spp. and enterococcal strains have underscored the importance of developing new candidate compounds for gram-positive organism infection (9) (10) (11) . Derivatives of the newer glycopeptide teicoplanin or similar structures that possess enhanced activity against the coagulase-negative staphylococci (CNS) and that maintain teicoplanin's superior potency against other gram-positive species have been recently described (5, 6) . Among these compounds, the amide modifications of the teicoplanin complex or its A2 component appear most active (6) . The greater potency seems to be secondary to better penetration into gram-positive bacterial cells (6 (3 strains), S. epidermidis (100 strains), S. haemolyticus (30 strains), S. hominis (20 strains), S. saprophyticus (10 strains), S. sciuri (2 strains), S. simulans (10 strains), S. warnerii (10 strains), and S. xylosus (2 strains). French isolates of CNS were not further identified. Forty-two anaerobic bacteria were also tested (see Table 2 ). Bacteroides fragilis group species included B. fragilis (20 strains), B. distasonis (2 strains), B. ovatus (1 strain), B. thetaiotaomicron (8 strains), and B. vulgatus (2 strains).
Susceptibility testing. A common lot of broth microdilution trays was prepared (Prepared Media Laboratories, Tualatin, Ore.) and shipped at -60°C to both study locations. MICs were determined by the method recommended by the National Committee for Clinical Laboratory Standards (NCCLS) with an inoculum of 5 x 105 CFU/ml in Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.) (7) . Oxacillin MICs were determined in cation-adjusted broth further supplemented with 2% NaCl. The 42 anaerobic bacteria were tested on Wilkins-Chalgren agar by the method described in NCCLS approved standard Mll-A (7) . Oxacillin resistance was defined as an MIC for the strain of >2 pug/ml, and vancomycin resistance was defined as an MIC for the strain of >8 pLg/ml. Teicoplanin-resistant strains were defined as those strains for which MICs were >16 pLg/ml (2) , and susceptible strains were those for which MICs were . 8 [Lg/ml. Since MDL 62211 and MDL 62873 were structurally related to teicoplanin, similar interpretive criteria were ten- tatively applied. Quality control strains were processed concurrently, as outlined by the NCCLS and the study protocol (7, 8) . MDL 62211 has previously been investigated by using an inducibly vancomycin-resistant Enterococcus faecium isolate (10, 11) . The MDL 62211 MIC for that strain was 0.13 jig/ml, 4-fold lower than teicoplanin and 256-fold lower than the MIC indicating vancomycin resistance. The vancomycin resistance was not induced by MDL 62211 (10, 11) . In addition, Capodicasa and colleagues (1) showed no adverse effects of MDL 62211 or teicoplanin on human polymorphonuclear cell activity. MDL 62873 activity has only been reported by Hunter et The results described and reviewed here show promise for the new amide derivatives of the teicoplanin A2 complex that appear to enhance activity against those CNS for which teicoplanin MICs are the highest, e.g., >16 ,ug/ml (4) . Clinical trials with one or both of these compounds should be considered if they are found to possess low toxicity and have the favorable pharmacokinetics of the parent drug.
